PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19464421-8	2009	Eplerenone, after covariate adjustment, significantly decreased MMP-2 and increased MMP-9 over 24 weeks relative to placebo.	Eplerenone	0-10	matrix metallopeptidase 9	Homo sapiens	84-89	
22742718-0	2012	Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone.	Eplerenone	183-193	matrix metallopeptidase 9	Homo sapiens	14-40	
22742718-7	2012	However, a significant beneficial eplerenone effect on outcome was observed in patients with low baseline levels of MMP-9 (event-free survival for eplerenone vs noneplerenone arm 65% vs 35%, p = 0.005).	Eplerenone	34-44	matrix metallopeptidase 9	Homo sapiens	116-121	
22742718-7	2012	However, a significant beneficial eplerenone effect on outcome was observed in patients with low baseline levels of MMP-9 (event-free survival for eplerenone vs noneplerenone arm 65% vs 35%, p = 0.005).	Eplerenone	147-157	matrix metallopeptidase 9	Homo sapiens	116-121	
22742718-9	2012	In conclusion, in patients after AMI with preserved LV systolic function, low baseline levels of MMP-9 identify a subgroup of patients in whom eplerenone use is associated with a survival benefit.	Eplerenone	143-153	matrix metallopeptidase 9	Homo sapiens	97-102